Taki T, Yamamoto K, Takamatsu M, Ishii K, Myoga A, Sekiguchi K, Ikeda I, Kurata K, Nakayama J, Handa S
Department of Biochemistry, School of Pharmaceutical Science, University of Shizuoka, Japan.
Cancer Res. 1990 Feb 15;50(4):1284-90.
Gangliosides of hepatomas have been analyzed by using a monoclonal antibody directed to N-acetylneuraminosyl(alpha 2-6)lactoneotetraosylceramide (sialyl(alpha 2-6)paragloboside), which was prepared by injecting the monosialoganglioside fraction of human meconium into BALB/c mice. The monoclonal antibody, named MSG-15, was found to bind sialyl(alpha 2-6)paragloboside, but it failed to react with other gangliosides, including N-acetylneuraminosyl(alpha 2-3)lactoneotetraosylceramide (sialyl (alpha 2-3)paragloboside) and "Ii"-type gangliosides. MSG-15 was found to recognize NeuAc alpha 2-6Gal beta structure of the ganglioside. Gangliosides obtained from human hepatomas were analyzed by immunostaining on high-performance thin-layer chromatography plates using the monoclonal antibody MSG-15. All primary hepatoma samples used in this study (nine samples) were found to contain sialyl(alpha 2-6)paragloboside, which accounted for 13-31% of the monosialoganglioside fractions in the hepatomas. Furthermore, MSG-15 recognized several monosialogangliosides in addition to sialyl(alpha 2-6)paragloboside. These gangliosides apparently also contain a terminal NeuAc alpha 2-6Gal beta structure. Other ganglioside fractions obtained from hepatoma and meconium were immunostained on thin layer chromatography plates with MSG-15. Additionally, another monoclonal antibody (H-11), which recognizes terminal lactosamine structure, was used to immunostain these fractions after sialidase treatment. Bands stained with both monoclonal antibodies showed similar mobilities to each other in the di- and trisialoganglioside fractions as well as monosialoganglioside fraction. In control liver, GM3 ganglioside accounted for 92% of monosialoganglioside fraction, and sialyl(alpha 2-6)paragloboside accounted for less than 1% of the fraction. Immunohistochemical study by using MSG-15 in tissue sections from hepatocellular carcinoma and normal liver tissues demonstrated that only hepatocellular carcinoma cells gave a positive reaction. These results suggest that the biosynthetic pathway of gangliosides containing NeuAc alpha 2-6Gal beta 1-4GlcNAc beta structure is activated in hepatoma cells.
通过使用一种针对N-乙酰神经氨酸(α2-6)乳糖新四糖神经酰胺(唾液酸(α2-6)副球蛋白苷)的单克隆抗体,对肝癌神经节苷脂进行了分析。该单克隆抗体是通过将人胎粪的单唾液酸神经节苷脂部分注射到BALB/c小鼠体内制备的。发现名为MSG-15的单克隆抗体能与唾液酸(α2-6)副球蛋白苷结合,但不与其他神经节苷脂反应,包括N-乙酰神经氨酸(α2-3)乳糖新四糖神经酰胺(唾液酸(α2-3)副球蛋白苷)和“Ii”型神经节苷脂。发现MSG-15能识别神经节苷脂的NeuAcα2-6Galβ结构。使用单克隆抗体MSG-15在高效薄层色谱板上通过免疫染色分析了从人肝癌中获得的神经节苷脂。本研究中使用的所有原发性肝癌样本(9个样本)均发现含有唾液酸(α2-6)副球蛋白苷,其占肝癌中单唾液酸神经节苷脂部分的13%-31%。此外,MSG-15除了能识别唾液酸(α2-6)副球蛋白苷外,还能识别几种单唾液酸神经节苷脂。这些神经节苷脂显然也含有末端NeuAcα2-6Galβ结构。用MSG-15在薄层色谱板上对从肝癌和胎粪中获得的其他神经节苷脂部分进行免疫染色。此外,另一种识别末端乳糖胺结构的单克隆抗体(H-11)在唾液酸酶处理后用于对这些部分进行免疫染色。用两种单克隆抗体染色的条带在二唾液酸和三唾液酸神经节苷脂部分以及单唾液酸神经节苷脂部分中彼此显示出相似的迁移率。在对照肝脏中,GM3神经节苷脂占单唾液酸神经节苷脂部分的92%,而唾液酸(α2-6)副球蛋白苷占该部分的比例不到1%。使用MSG-15在肝细胞癌和正常肝组织的组织切片中进行免疫组织化学研究表明,只有肝癌细胞呈阳性反应。这些结果表明,含有NeuAcα2-6Galβ1-4GlcNAcβ结构的神经节苷脂的生物合成途径在肝癌细胞中被激活。